Sinphar Pharmaceutical Co. Ltd.
1734.TW
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.53B
Close$
Share Statistics
| Market cap | $6.53 Billion |
|---|---|
| Enterprise Value | $7.20 Billion |
| Dividend Yield | $0.94 (2.91%) |
| Earnings per Share | $1.92 |
| Beta | 0.07 |
| Outstanding Shares | 187,714,000 |
Return
| Return on Equity | 10.20% |
|---|---|
| Return on Assets | 5.14% |
| Return on Invested Capital | 8.14% |
Valuation & Multiples
| P/E Ratio | 17.42 |
|---|---|
| PEG | 48.38 |
| Price to Sales | 1.8 |
| Price to Book Ratio | 1.71 |
| Enterprise Value to Revenue | 2.09 |
| Enterprise Value to EBIT | 16.75 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sinphar Pharmaceutical Co. Ltd.
1,829 employees
CEO: Yu-Liang Pei Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Viet...